About Axikin
Axikin is a Healthcare company based in San Diego (United States) founded in 2008. US-based, clinical-stage biopharma developing chemokine receptor targeting small molecules for respiratory, inflammatory and autoimmune diseases. Axikin has raised $12.5 million across 4 funding rounds from investors including Sanderling Ventures and Mitsui Ventures. The company has 2 employees. Its chief executive, as recorded, is Peter McWilliams. Its focus areas include Life Sciences, Pulmonology, Drugs and COPD and Asthma. Its legal entity is Axikin Pharmaceuticals, Inc. Its competitors include MediciNova, TFF Pharmaceuticals and Theravance Biopharma; 2 of its 3 listed competitors have raised funding.
Company details
Axikin Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, was founded in 2008 in San Diego, United States, via spin-out from Actimis Pharmaceuticals. Small molecules targeting chemokine receptors, including the lead candidate AXP1275an oral allosteric modulator of the CCR3 receptorare advanced for respiratory, inflammatory, and autoimmune conditions. AXP1275 is currently in Phase II trials.
- Headquarters San Diego, United States
- Employees 2
- SectorsHealthcare
- Website axikin.com
- Social LinkedIn
- Legal Name Axikin Pharmaceuticals, Inc.
- Total Equity Funding$12.5M (USD)
in 4 rounds
- Latest Funding Round$6.5M (USD), Series B
Sep 2015
- InvestorsSanderling Ventures
& 1 more
- Employee Count2
Funding Insights of Axikin
Axikin has successfully raised a total of $12.5M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $6.5 million completed in September 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.5M
- Total Rounds 4
- Last Round Series B — $6.5M
- First Round $3M
(Jan 2009)
- Investors Count 2
All 4 funding rounds of Axikin with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2015 | $6.5M | Series B | – | – | – |
| Mar 2012 | $2M | Series A | – | – | – |
| Aug 2010 | $1M | Series A | – | – | – |
| Jan 2009 | $3M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Axikin
Axikin has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Sanderling Ventures and Mitsui Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biomedical investment financing and active management services. | sanderling.com | |||
| mitsuiventures.com |
Investor details for Axikin
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Axikin
1 people are tracked at Axikin (1 in leadership); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Peter McWilliams | CEO | Leadership |
Complete people profiles for Axikin
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Axikin
3 dated milestones of Axikin across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Axikin is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Series B, of $6.5M.
Competitors of Axikin
Axikin has 3 listed competitors in our database, 2 of them funded. They include MediciNova, TFF Pharmaceuticals and Theravance Biopharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| medicinova.com | 2000 | San Diego, United States | $83.94M | 13 | Small-molecule therapeutics are developed for asthma, COPD, and neurologic diseases. | |
| tffpharma.com | 2018 | Austin, United States | $22.17M | 15 | Developer of inhalation products for chronic respiratory diseases | |
| theravance.com | 2001 | Francisco, United States | 99 | Therapeutics for inflammatory and immunological diseases are developed. |
Detailed competitors of Axikin
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pulmonology
3 companies that operate in the same segment as Axikin (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Axikin
Axikin was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Axikin is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Peter McWilliams is the CEO of Axikin, as recorded in our data.
Axikin is a funded company, having raised a total of $12.5M across 4 funding rounds to date. The company's 1st funding round was a Series A of $3M, raised on Jan 2009.
Axikin has 2 employees.
Axikin Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, was founded in 2008 in San Diego, United States, via spin-out from Actimis Pharmaceuticals. Small molecules targeting chemokine receptors, including the lead candidate AXP1275an oral allosteric modulator of the CCR3 receptorare advanced for respiratory, inflammatory, and autoimmune conditions. AXP1275 is currently in Phase II trials.
Axikin's top competitors include TFF Pharmaceuticals, Theravance Biopharma and MediciNova.
Axikin has 2 investors. Key investors include Sanderling Ventures, and Mitsui Ventures.
Axikin operates through Axikin Pharmaceuticals, Inc..